Real-time enrollment status for this atrial fibrillation (af) clinical trial
Current Status
Recruiting
Checked: October 9, 2026 at 8:56 PM UTC
| NCT Number | NCT07626411 |
| Recruiting Status | Recruiting |
| Condition | Atrial Fibrillation (AF) |
| Phase | PHASE3 |
| Target Enrollment | 15,364 participants |
| Active Locations | 44 sites in the US |
| Sponsor | Regeneron Pharmaceuticals |
| Last Updated on CT.gov | October 8, 2026 (Yesterday) |
As of October 9, 2026: Clinical trial NCT07626411 is currently recruiting participants. This phase3 study for atrial fibrillation (af) is actively seeking new participants at 44 locations across the United States. The study is sponsored by Regeneron Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07626411 is actively recruiting participants as of October 9, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 44 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07626411 was last updated Yesterday (October 8, 2026). HelloStudys verifies this status automatically.